USCOM LIMITED — Capital/Financing Update 2017

Jan 2, 2017

ASX Media Release

Uscom ends 2016 with record manufacturing

SYDNEY, Australia, Tuesday 3[rd] January 2017: Uscom Limited (ASX code: UCM) (the Company or Uscom ) today notified the market that Uscom manufactured record numbers of USCOM 1A devices for the month of December 2016 and for the first half of FY 2017 to meet orders into Chinese, European and US clinical markets. In addition Uscom completed the manufacture of its 1,000[th] USCOM 1A cardiovascular monitor.

Manufacturing summary

• December month - record manufactured units

• December quarter – record manufactured units (42% of annual FY 2016 manufacturing)

• December half – up 28% on prior half

• 1000[th] USCOM 1A manufactured

Uscom manufactured a record number of USCOM 1A units for the month of December 2016, and in the second quarter of FY 2017. December quarterly manufacturing represented 42% of the total devices manufactured annually in FY 2016. The number of units manufactured in the first half of FY 2017 increased by 28% on the previous half and Uscom delivered its 1000[th] USCOM 1A device into global markets.

Uscom is anticipating the sequential commercial release of its new BP+ and BP+ Reporter and SpiroSonic series of devices and the accompanying SpiroReporter software into the Chinese, European and US markets over the next twelve months as regulatory permissions are received. CE approval for the SpiroSonic devices was received last month, with other approvals at various stages of preparation, submission and review. To date all revenue and revenue growth has predominantly been attributable to USCOM 1A sales.

Executive Chairman of Uscom, Associate Professor Rob Phillips said “Uscom is a milestone driven company, and despite complex global dynamics we are continuing our outstanding growth trends into the 5[th] consecutive year. We are currently preparing for the manufacture and sale of the BP+ and SpiroSonic series of devices into global markets as regulatory approvals are granted. This will involve transitioning to volume manufacturing to meet the current increased demand and the anticipated new demand; a change that will improve supply and margins. It’s really satisfying that our USCOM 1A device is now being adopted worldwide in significant numbers to save the lives of children and adults, and remains an innovative cornerstone of advanced haemodynamics – we have effectively changed clinical practice. We anticipate the BP+ and SpiroSonic devices will do the same in complimentary clinical settings and start significantly contributing to revenue over the next 12 months.“

Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are sold into global medical markets, changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertension and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

ASX Media Release

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au

Brett Crowley Company Secretary secretary@uscom.com.au

Uscom Limited (ABN 35 091 028 090) Suite 1, Level 7, 10 Loftus Street , Sydney NSW 2000 Australia , T +612 9247 4144 F +612 9247 8157 www.uscom.com.au